toh

After receiving the Cancer Care Ontario safety bulletin, The Ottawa Hospital undertook a review of patients regarding the administration of three systemic treatment drugs (Pembrolizumab, Nivolumab, and Panitumumab).

The Ottawa Hospital is the hub for cancer care in Eastern Ontario. A review identified the patients who may have received a lower-than-intended dose. Those patients have been notified, with the exception of estate representatives for the deceased. In those instances, the hospital is in the process of notification.

The medical team has conducted a thorough chart review for each patient. Based on analysis done by cancer experts, no harm could be attributed to the reduced doses, and no patient’s regimen has changed.